Early Access — free while we kick the tires
EdgarHawk

Cheryl Cohen

Director

Director

Latest: Director selling · July 2026

1 filing analyzed · 1 company · Latest 2026-07-06

Never miss a filing from Cheryl Cohen

Watch this insider and we'll alert you the moment they file — at any company.

Companies

Company Buys Sells Direction
ImmunityBio, Inc. IBRX 0 2 Net selling

Activity

July 2026
2026-07-06 ImmunityBio, Inc. IBRX 10b5-1 Plan
medium
Sell
131,210 shares
$1,246,941
Significance 6/10

Director Cheryl Cohen sold 131,210 shares (131.2K) of IBRX at $9.50 on 2026-07-02 via scheduled 10b5-1 plan; retains 125,386 non-derivative shares plus 111,958 stock options.

Director Cheryl Cohen executed a scheduled sale of 131,210 shares at $9.50, reducing her non-derivative holdings by 51.1% to 125,386 shares. The transaction was part of a pre-arranged 10b5-1 trading plan and therefore represents a scheduled divestment rather than a discretionary decision. While the stock has climbed 28.8% over the prior 30 days and 29.9% over the prior 90 days from the sale date, the underlying company reported a net loss of $632.8M in its most recent full fiscal year, despite posting strong annual revenue growth of 668.3%. Cohen retains meaningful exposure through 111,958 stock options, indicating continued economic alignment with the company even after the partial share reduction.

Related insiders